In vivo transgenic mutation assays

被引:95
作者
Thybaud, W [1 ]
Dean, S
Nohmi, T
de Boer, J
Douglas, GR
Glickman, BW
Gorelick, NJ
Heddle, JA
Heflich, RH
Lambert, L
Martus, HJ
机构
[1] Aventis Pharma, Drug Safety Evaluat, Vitry Sur Seine, France
[2] Huntingdon Life Sci, Huntingdon, Cambs, England
[3] Natl Inst Hlth Sci, Div Genet & Mutagenesis, Tokyo 158, Japan
[4] Univ Victoria, Ctr Biomed Res, Victoria, BC, Canada
[5] Hlth Canada, Ctr Environm Hlth, Mutagenesis Sect, Ottawa, ON K1A 0L2, Canada
[6] York Univ, Dept Biol, Toronto, ON M3J 2R7, Canada
[7] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA
[8] Novartis Pharma AG, Genet Toxicol& Funct Validat, Basel, Switzerland
[9] SRI Int, Toxicol Lab, Menlo Pk, CA 94025 USA
[10] Natl Inst Hlth, Div Cellular & Gene Therapy Prod, Tokyo 141, Japan
[11] Snow Brand Labio Co Ltd, Inst Res & Dev, Aichi, Japan
关键词
D O I
10.1016/j.mrgentox.2003.07.004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Transgenic rodent gene-mutation models provide relatively quick and statistically reliable assays for gene mutations in the DNA from any tissue. This report summarizes those issues that have been agreed upon at a previous IWGT meeting [Environ. Mol. Mutagen. 35 (2000) 253], and discusses in depth those issues for which no consensus was reached before. It was previously agreed that for regulatory applications, assays should be based upon neutral genes, be generally available in several laboratories, and be readily transferable. For phage-based assays, five to ten animals per group should be analyzed, assuming a spontaneous mutant frequency (MF) of similar to3 x 10(-5) mutants/locus and 125,000-300,000 plaque or colony forming units (pfu or cfu) per tissue per animal. A full set of data should be generated for a vehicle control and two dose groups. Concurrent positive control animals are only necessary during validation, but positive control DNA must be included in each plating. Tissues should be processed and analyzed in a blocked design, where samples from negative control, positive control and each treatment group are processed together. The total number of pfus or cfus and the MF for each tissue and animal are reported. Statistical tests should consider the animal as the experimental unit. Nonparametric statistical tests are recommended. A positive result is a statistically significant dose-response and/or statistically significant increase in any dose group compared to concurrent negative controls using an appropriate statistical model. A negative result is a statistically non-significant change, with all mean MFs within two standard deviations of the control. During the current workshop, a general protocol was agreed in which animals are treated daily for 28 consecutive days and tissues sampled 3 days after the final treatment. This recommendation could be modified by reducing or increasing the number of treatments or the length of the treatment period, when scientifically justified. Normally male animals alone are sufficient and normally at least one rapidly proliferating and one slowly proliferating tissue should be sampled. Although, as agreed previously, sequencing data are not normally required, they might provide useful additional information in specific circumstances, mainly to identify and correct for clonal. expansion and in some cases to determine a mechanism associated with a positive response. (C) 2003 Elsevier B.V All rights reserved.
引用
收藏
页码:141 / 151
页数:11
相关论文
共 69 条
[61]   COMPARISON OF SOMATIC MUTATION IN A TRANSGENIC VERSUS HOST LOCUS [J].
TAO, KS ;
URLANDO, C ;
HEDDLE, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (22) :10681-10685
[62]   MUTAGENICITY OF METHYL METHANESULFONATE (MMS) IN-VIVO AT THE DLB-1 NATIVE LOCUS AND A LACI TRANSGENE [J].
TAO, KS ;
URLANDO, C ;
HEDDLE, JA .
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 1993, 22 (04) :293-296
[63]   Effect of mitogenic or regenerative cell proliferation on lacz mutant frequency in the liver of Muta™Mice treated with 5,9-dimethyldibenzo[c,g]carbazole [J].
Tombolan, F ;
Renault, D ;
Brault, D ;
Guffroy, M ;
Périn, F ;
Thybaud, V .
CARCINOGENESIS, 1999, 20 (07) :1357-1362
[64]   Kinetics of induction of DNA adducts, cell proliferation and gene mutations in the liver of Muta™Mice treated with 5,9-dimethyldibenzo[c,g]carbazole [J].
Tombolan, F ;
Renault, D ;
Brault, D ;
Guffroy, M ;
Périn-Roussel, O ;
Périn, F ;
Thybaud, V .
CARCINOGENESIS, 1999, 20 (01) :125-132
[65]  
Vijg Jan, 1996, P391
[66]   Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in B6C3F1/Tk+/- mice treated neonatally with zidovudine and lamivudine [J].
Von Tungeln, LS ;
Hamilton, LP ;
Dobrovolsky, VN ;
Bishop, ME ;
Shaddock, JG ;
Heflich, RH ;
Beland, FA .
CARCINOGENESIS, 2002, 23 (09) :1427-1432
[67]   A CLONAL MARKER INDUCED BY MUTATION IN MOUSE INTESTINAL EPITHELIUM [J].
WINTON, DJ ;
BLOUNT, MA ;
PONDER, BAJ .
NATURE, 1988, 333 (6172) :463-466
[68]  
Wolff T, 2001, ADV EXP MED BIOL, V500, P687
[69]   Intestinal mutagenicity of two carcinogenic food mutagens in transgenic mice: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and amino(alpha)carboline [J].
Zhang, XB ;
Felton, JS ;
Tucker, JD ;
Urlando, C ;
Heddle, JA .
CARCINOGENESIS, 1996, 17 (10) :2259-2265